Delhi NCR, 29 July 2025: In a significant advancement towards precision medicine, Fortis Memorial Research Institute (FMRI), Gurugram, in collaboration with Agilus Diagnostics, has launched its second Genexus system, further strengthening the nation’s fastest and most scalable rapid genomic testing program. This milestone reinforces Fortis’ and Agilus’ shared commitment to transforming cancer care through cutting-edge diagnostics and timely, mutation-matched treatment decisions.
The Genexus platform enables Next-Generation Sequencing (NGS) with an unparalleled turnaround time – delivering crucial results such as Liquid Biopsy in 24 hours, Myeloid NGS in 72 hours, and MRD testing within 5 days. These timeframes significantly outperform traditional diagnostic methods, which often take weeks and offer limited insight into genetic complexity.
“With the addition of the second Genexus system, we can now scale our rapid NGS workflow for AML and other hematologic malignancies across more patients and regions,” said Dr. Rahul Bhargava, Principal Director and Chief – Haematology and Bone Marrow Transplant, Fortis Memorial Research Institute, Gurugram. “Genomics is not the future anymore – it is the present. Every mutation tells a story. With faster and deeper insights, we’re not only making better treatment decisions but also giving our patients a genuine shot at survival and long-term remission.”
Thanks to the rapid NGS (Next-Generation Sequencing) program at Fortis and Agilus, doctors can now uncover the genetic reasons behind a person’s cancer in just a few days – something that used to take weeks. This breakthrough has led to real and meaningful improvements in patient care:
- Patients start the right treatment much sooner – With faster test results, doctors can match patients to the most effective, personalized treatments based on their unique genetic profile. In fact, over 40% of patients received targeted therapies, compared to just 11% earlier when results took much longer.
- Life-saving transplants are happening earlier – For patients who need a bone marrow transplant, everyday counts. Before this program, most patients waited nearly 4 months before they could proceed. Now, with faster diagnostics, that wait has dropped to under 3 months – giving patients a better chance at recovery.
- Fewer patients are dying in the first month of treatment – Early treatment decisions are critical in blood cancers like leukaemia. With rapid test results, doctors can act quickly cutting the number of early deaths (within 30 days of diagnosis) by more than half.
- More patients are living longer – After one year, survival rates were 8% higher among patients who benefited from the rapid NGS program. That’s a significant improvement and offers new hope to patients and families battling aggressive cancers.
Genomics is no longer a future dream – it’s saving lives today. With Genexus 2.0, Fortis and Agilus are leading the charge in making precision cancer care faster, smarter, and more accessible for every patient.
Dr. Anand K, MD & CEO, Agilus Diagnostics, said, “With the second Genexus system in place, we are better positioned to democratize access to advanced molecular diagnostics, delivering not just results, but truly actionable insights in record time. This marks a critical step in bringing personalized medicine closer to every Indian cancer patient.”
Powered by Fortis’ clinical excellence and Agilus’ national laboratory infrastructure, this collaboration brings together haematologists, oncologists, molecular pathologists, and bioinformaticians under one umbrella. The goal: to ensure that no patient waits unnecessarily for life-saving genomic results.
As Fortis and Agilus accelerate the rollout of AI-enabled genomics and integrated tumour boards, the addition of this new system marks a leap forward in India’s journey toward precision oncology at scale.
